Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 17/20 | 0.72 |
| ▸ | CASP3 | P42574 | 1/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.59 |
| ▸ | NT5E | P21589 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3614716 | 0.98 | KIF11 (0.72) | KIF11CASP3KCNH2NT5E | |
| SCHEMBL3618256 | 0.91 | KIF11 (0.69) | KIF11CASP3KCNH2NT5E | |
| SCHEMBL3620833 | 0.91 | KIF11 (0.69) | KIF11CASP3KCNH2NT5E | |
| SCHEMBL13315413 | 0.86 | KIF11 (0.68) | KIF11CASP3KCNH2NT5E | |
| SCHEMBL3624174 | 0.84 | KIF11 (1.00) | KIF11CASP3KCNH2NT5E | |
| SCHEMBL3616984 | 0.84 | KIF11 (0.79) | KIF11CASP3KCNH2NT5E | |
| SCHEMBL3626735 | 0.81 | KIF11 (1.00) | KIF11CASP3KCNH2NT5E | |
| SCHEMBL5672186 | 0.81 | KIF11 (0.71) | KIF11CASP3KCNH2 | |
| SCHEMBL3624468 | 0.80 | KIF11 (0.55) | KIF11CASP3KCNH2NT5E | |
| SCHEMBL5671359 | 0.80 | KIF11 (0.63) | KIF11CASP3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1492487-A4 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2006-01-11 | — | — | EP | claimed |
| US-20050119484-A1 | Mitotic kinesin inhibitors | MERCK SHARP & DOHME CORP. | 2005-06-02 | — | — | US | claimed |
| EP-1492487-A2 | MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2005-01-05 | — | — | EP | claimed |
| WO-2003079973-A2 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2003-10-02 | — | — | WO | claimed |
| US-7745639-B2 | Mitotic kinesin inhibitors | MERCK & CO., INC. (US) | 2010-06-29 | — | — | US | disclosed |
| US-20050119484-A1 | Mitotic kinesin inhibitors | MERCK SHARP & DOHME CORP. | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119484-A1 | Mitotic kinesin inhibitors | KIF5B, KIF2C, KIF23 | KIF11 8/4885CASP3 2677/4885KCNH2 1656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.